A diverse collection of 123 meningococcal and 126 gonococcal isolates was tested for susceptibility to N-formimidoyl thienamycin (N-F-thienamycin; MK0787) and to penicillin G (PEN). All of the meningococci were susceptible to both of these, as well as to rifampin. Among gonococci, P-lactamase-producing strains, which were resistant to PEN, were susceptible to N-F-thienamycin.
Among non-p-lactamase-producing strains, the minimal inhibitory concentrations of N-F-thienamycin and PEN were s1.28 ,g/ml. Of these, the strains with PEN minimal inhibitory concentrations toward the higher end of the range were likely to be more susceptible to N-F-thienamycin, whereas the strains that were highly susceptible to PEN were likely to have higher minimal inhibitory concentrations of N-F-thienamycin.
N-Formimidoyl thienamycin (N-F-thienamycin; MK0787) is a stable derivative of the new 0lactam antibiotic thienamycin. Previous studies have shown that N-F-thienamycin has potent antimicrobial activity against a broad range of bacteria (5, 7) . This report presents in vitro susceptibility data on a wide variety of clinical isolates of Neisseria meningitidis and Neisseria gonorrhoeae tested with N-F-thienamycin and, for comparison, with other antibiotics currently used in the treatment of infections caused by these species. matched randomly to these strains by the same auxotype. PPNG were identified by testing with the chromogenic cephalosporin, nitrocefin (kindly provided by Glaxo Research, Ltd.). All gonococcal and meningococcal isolates were stored at -86°C in a solution of 1:1 heat-inactivated horse serum (GIBCO Diagnostics) and tryptic soy broth. N-F-thienamycin was supplied by Merck Sharp & Dohme, rifampin (RIF) was supplied by Ciba Pharmaceutical Co., and tetracycline (TET) was supplied by Lederle Laboratories. Penicillin G (PEN) was purchased from Parke-Davis. N-F-thienamycin and PEN solutions were prepared on the day they were used. N-Fthienamycin was dissolved in 10 mM potassium phosphate buffer (pH 7.2).
The MIC of each antibiotic for each strain was determined by an agar dilution method. All strains were subcultured from frozen suspensions onto either tryptic soy agar plus 7.5% horse serum or commercially prepared chocolate agar (Scott Laboratories, Inc.), and the plates were incubated in candle jars at 37°C for pending in tryptic soy broth to a final concentration of approximately 5 x 107 colony-forming units per ml. These inocula were applied with a Steers replicator (9) to tryptic soy agar plus 7.5% horse serum containing antibiotics in the following ranges of concentrations (in ,ug/ml) in serial twofold dilutions: N-F-thienamycin and PEN, 0.01 to 0.16 for N. meningitidis and 0.005 to 2.56 for N. gonorrhoeae; RIF, 0.031 to 1.0 for N. meningitidis; and TET, 0.25 to 8.0 for N. gonorrhoeae. After the plates were incubated in candle jars at 37°C for 24 h, the MIC was taken as the lowest concentration of antibiotic which allowed growth of fewer than six colonies. Table 1 summarizes the susceptibility of the N. meningitidis isolates to PEN, N-F-thienamycin, and RIF. Virtually all of the strains were inhibited by concentrations of PEN that are easily achieved in the serum and CSF of patients. All of these strains were inhibited by the same concentrations of N-F-thienamycin, which are also easily achieved in humans (F. Follath, Agents Chemother. 21st, Chicago, Ill., abstr. no 590, 1981). The vast majority of isolates were also very susceptible to RIF.
Table 1 also summarizes the susceptibility of AHU and PPNG gonococcal isolates and the other 100 strains of N. gonorrhoeae to PEN, N-F-thienamycin, and TET. AHU strains were exquisitely susceptible to PEN, as expected (6, 8) , and were generally very susceptible to N-Fthienamycin and TET as well. The MICs of N-F-thienamycin and PEN for these strains were comparable to those for N. meningitidis. Despite their resistance to PEN, the PPNG strains were very susceptible to N-F-thienamycin, with a narrow range of MICs at the upper end of the range of MICs for AHU strains. The collection of non-PPNG strains of non-AHU auxotypes ("other") appeared to have similar susceptibility to PEN and N-F-thienamycin, although individual strains differed in susceptibility to the two drugs. Figure 1 depicts the susceptibility of each gonococcal isolate to PEN and to N-F-thienamycin. Regression analysis showed that even with the PPNG isolates omitted, strains with MIC of PEN >0.16 ,ug/ml tended to be more susceptible to N-F-thienamycin, whereas strains with MIC of PEN <0.16 ,ug/ml were likely to be less susceptible to N-F-thienamycin. Omission of the AHU strains had little effect. The groups of PPNG isolates and other non-AHU strains were slightly less susceptible to TET than AHU isolates (Table 1) , but they were all inhibited by concentrations achievable in blood with oral therapy.
Our diverse meningococcal isolates were all very susceptible to N-F-thienamycin, but they were also comparably susceptible to PEN and RIF. A recent study of 103 meningococcal isolates showed similar 50% MIC-to-90% MIC ratios (MIC50MIC90) of N-F-thienamycin and of PEN, 0.125/0.25 and 0.25/0.5, respectively (2); these relatively low MIC50 and MIC%0 values were around three times higher than those in our study, but this small discrepancy probably does not reflect any important differences. Against our PPNG strains, N-F-thienamycin was clearly superior to PEN, and even to TET.
A recent study of 50 PPNG showed an MIC90 of N-F-thienamycin of 0.25 ,ug/ml (2), which is similar to that of our strains. All of our non-PPNG isolates were inhibited by 1.28 ,ug of N-Fthienamycin or PEN per ml; excluding the AHU isolates, which were all exquisitely susceptible, the MIC90 values of N-F-thienamycin and PEN were both 0.64 ,ug/ml. In comparison, recent studies of non-PPNG showed MIC90 values of N-F-thienamycin and PEN to be, respectively, 0.25 and 1.0 ,ug/ml (2), 0.5 and 1.0 ,ug/ml (3), and 0.03 and 0.25 ,ug/ml (1). The proportions of AHU isolates in these other collections of strains are not defined. Although infections with strains whose MICs of PEN lie at the upper end of the range seen in our study are treatable with penicillin regimens, one might expect a lower rate of cure than with more susceptible strains. Many of these strains that are less susceptible to PEN have lower MICs of N-F-thienamycin. Conversely, the more PEN-susceptible strains have higher MICs of N-F-thienamycin. The other studies of N-F-thienamycin and PEN against gonococci (1-3) did not compare the activity of the two drugs against individual isolates, so one cannot examine such an association in the data that were reported. On the basis of our study and these other reported studies, N-F-thienamycin might be useful in the treatment of gonococcal infections, especially where PPNG may be expected. Further testing of additional non-PPNG strains that are relatively less susceptible to PEN may resolve whether N-F-thienamycin is clearly more advantageous for such strains.
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